Home Compare GALD.SW vs NBIX
Stock Comparison · Industry comparison · Drug Manufacturers - Specialty

GALD.SW vs Neurocrine Biosciences: Which Stock Looks Stronger in 2026?

Neurocrine Biosciences holds the cleaner structural position, with valuation as the main driver and growth adding further support. GALD.SW does not offset that deficit through any equally strong structural edge elsewhere. The market setup is broadly comparable for both — no clear directional signal from price behavior. The market is not adding a decisive signal either way — the structural read carries the weight.

The comparison is based on similar long-term financial trajectories, not sector labels. Peer scores are normalised within each company's primary universe (GALD.SW: STOXX 600, NBIX: Russell 1000).

Updated 2026-05-17

Most of the visible separation comes from valuation. The overall score gap is 23 points in favour of Neurocrine Biosciences, Inc..

INDUSTRY COMPARISON

Both operate in: Drug Manufacturers - Specialty & Generic

This comparison is based on industry proximity, not on functional trajectory similarity. GALD.SW and NBIX share the same industry classification.

For a similarity-based comparison, see how GALD.SW and Neurocrine Biosciences each position within their functional peer groups in AssetNext.

Peer-Relative Score
GALD.SW
GALD.SW
43
Peer-Score
Signal qualitylow
Peer basis: STOXX 600
vs
NBIX
Neurocrine Biosciences, Inc.
66
Peer-Score
Signal qualitylow
Peer basis: Russell 1000

Scores reflect position relative to comparable companies with similar long-term financial trajectories.

The largest gaps do not all point in the same direction.

Dimension spread: GALD.SW vs NBIX Profitability 29 33 Stability 64 74 Valuation 15 73 Growth 87 98 GALD.SW NBIX
Gap Ranking
#1 Valuation +58
#2 Growth +11
#3 Stability +10
#4 Profitability +4
Price Setup

Left means cheaper relative valuation. Higher means stronger structure.

Price setup map for GALD.SW and NBIX Stronger + cheaper Stronger + richer Weaker + cheaper Weaker + richer GALD.SWNBIX Relative valuation Structural strength

Neurocrine Biosciences, Inc. looks stronger on relative valuation, while the broader price setup remains mixed.

Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.

Relative Position vs Comparable Companies
Valuation
On valuation, Neurocrine Biosciences, Inc. ranks near the top of the group; GALD.SW sits in the weaker half.
Growth
Even on growth, where both profiles remain strong, GALD.SW still holds the higher peer position.
Valuation — Dominant Gap
GALD.SW
15
NBIX
73
Gap+58in favour of NBIX

The multiple-based pricing edge comes from a forward P/E that is 18.8 turns lower.

What keeps the gap from being one-sided

GALD.SW still shows lower market-fundamental divergence, which keeps the wider picture mixed rather than completely one-sided.

What this means for the comparison

Valuation is the clearest driver, and growth also supports Neurocrine Biosciences, Inc.'s broader structural position.

Explore full peer positioning in AssetNext

Break down the GALD.SW vs NBIX comparison across all dimensions with the full interactive tool.

Explore full breakdown →
Similar valuation-driven comparisons

Explore how GALD.SW and NBIX each compare against other companies in their peer groups.

Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.

How AssetNext Peer Scores Work

AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.

Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.

Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.

Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.